期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.764630
关键词
CD9; solid tumors; prognosis; overall survival; time to progression
类别
资金
- Fundamental Research Funds for the Central Universities [WK9110000177]
- National Natural Science Foundation [81773192, 82072712]
- Natural Science Foundation of Jiangsu Province [BK20171248]
- Jiangsu Youth Medical Talents Project [QNRC2016527]
This meta-analysis revealed a strong association between decreased CD9 expression and poor prognosis in solid tumors, particularly in lung cancer and head and neck cancer patients. CD9 may serve as a valuable prognostic predictive biomarker and potential therapeutic target in human solid tumors.
Numerous clinical studies investigated how low expression of CD9 predicts poor prognosis of solid tumor. However, the results were inconclusive. This present meta-analysis was therefore performed to determine the prognostic value of CD9 expression in solid tumors. In this meta-analysis, 25 studies involving 5,555 participants were included; the result showed strong significant associations between declined expression of CD9 and all endpoints: overall survival (OS) (hazard ratio (HR) = 1.88, 95% CI = 1.45-2.43, p < 0.000) and time to progression (TTP) (HR = 2.0, 95% CI = 1.38-2.88, p < 0.000). The subgroup analysis was also performed, which revealed that the associations between CD9 downregulated expression related to poor OS in lung cancer and head and neck cancer. Also, low expression of CD9 was significantly connected with poor TTP in patients with head and neck cancer. The adverse prognostic impact of decreased expression of CD9 was observed in patients of different ethnicities. In conclusion, these results showed that declined expression of CD9 was associated with poor survival in human solid tumors. CD9 may be a valuable prognostic predictive biomarker and a potential therapeutic target in human solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据